Metabolic associated fatty liver disease and COVID-19: a double whammy?
Saved in:
Main Authors: | Jaime Hui Xian Lin, Veeraraghavan Meyyur Aravamudan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer – Medknow Publications
2022-09-01
|
Series: | Singapore Medical Journal |
Online Access: | https://journals.lww.com/10.11622/smedj.2020141 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01) -
Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
by: Zhifeng Gao, et al.
Published: (2025-01-01) -
Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease
by: Sitong Yi, et al.
Published: (2023-01-01) -
Metabolic Profiles of the Gut Microbiota in Patients with Different Stages of Metabolism Dysfunction-Associated Fatty Liver Disease
by: X. Cao, et al.
Published: (2024-10-01) -
Prevalence and risk factors of liver fibrosis in patients with metabolic-associated fatty liver disease undergoing bariatric surgery
by: Amr Elsayed, et al.
Published: (2024-12-01)